Interim Phase 1/2 Data Show Encouraging Clinical Benefit for...

Interim Phase 1/2 Data Show Encouraging Clinical Benefit for...


Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb Company and Innate Pharma SA today announced an interim efficacy analysis from a Phase 1/2 study of the combination of lirilumab and Opdivo in the cohort of advanced platinum refractory squamous cell carcinoma of the head and neck , including exploratory biomarker analyses of patient response by level of PD-L1 expression. Among 29 evaluable patients with SCCHN, the objective response rate , a secondary endpoint measured by Response Evaluation Criteria In Solid Tumors , was 24% .



from Biotech News